Biotech / Pharma


CytoTools AGwww.cytotools.de
CytoTools is an investment and holding company in the biotechnology business with two associated companies. DermaTools Biotech (51.5% stake) focuses on drug development in dermatology and urology, whereas CytoPharma (46.0% stake) concentrates on R&D in cardiovascular diseases and cancer. We initiated coverage in December 2009.
Recent reports

Deutsche Biotech Innovativ AGwww.dbi-ag.de
Deutsche Biotech Innovativ AG (“DBI”) is a biotechnology company that utilizes innovative blood biomarkers to investigate and clinically develop unique therapies for severe disease without appropriate solutions, such as sepsis and cancer.
Recent reports

Formycon AGwww.formycon.com
Formycon AG is a Munich, Germany based pharmaceuticals company specializing in the development of biosimilars, e.g. generic versions of biotechnology products. We intiated coverage on Formycon AG in April 2013.
Recent reports

HAEMATO AGwww.haemato-ag.de
HAEMATO AG, a subsidiary of MPH Mittelständische Pharma Holding AG, is a pharma company focusing on the sale of generics and parallel imports in high priced niches. The company is targeting selected pharmaceutical products in a small number of clinical indications such as oncology or HIV. We intiated coverage on HAEMATO AG in August 2013.
Recent reports

Mologen AGwww.mologen.com
MOLOGEN AG is a R&D-stage biotechnology company based in Berlin. The firm focuses on innovative DNA-based drug development for the treatment of diseases with unmet medical need. We reinitiated coverage in January 2013.
Recent reports

Mittelständische Pharma Holding AGwww.mph-ag.de
MPH is a German based healthcare company specializing in the fields of pharmaceuticals, patient care, and cosmetic surgeries with a strategic focus on therapeutic areas of chronic diseases and lifestyle beautification. Rising healthcare costs in Germany are expected to continue driving demand for the inexpensive solutions provided by the company’s core healthcare activities.
Recent reports

NOXXON Pharma NV | www.noxxon.com
Noxxon Pharma NV is an immuno-therapeutic biotech company focused on the research and development of new drugs to treat cancer based on its proprietary Spiegelmer technology platform. The company is based in Berlin and currently has two drugs in phase I and phase II clinical trials to treat several types of cancer. We initiated coverage in November 2016.
Recent reports

Paion AGwww.paion.de
Paion AG is a biotech company based in Aachen, Germany, focusing on the discovery of new treatments for stroke and other thrombotic diseases. Through a search and development strategy the company seeks, acquires and in-licenses promising new compounds at an early stage in order to develop them through clinical trials. We initiated coverage in July 2005. We re-inititated coverage for DZ Bank in 2009.
Recent reports

Pharming Group NVwww.pharming.com
Pharming Group NV is a Dutch biopharmaceutical company developing and producing therapeutic proteins in the milk of genetically modified animals. Pharming currently has two candidates in late-stage development: recombinant human C1 inhibitor for HAE and recombinant human Lactoferrin for nutritional use. We initiated coverage in July 2004.
Recent reports

Sirona Biochem Corp | www.sironabiochem.com
Vancouver-based Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. The firm’s laboratory, TFChem, is located in France and specialises in stabilising carbohydrate molecules with the goal of improving efficacy and safety. We initiated coverage in January 2015.
Recent reports

Valneva SE | www.valneva.com
Valneva is a fully integrated, commercial stage biotech company focused on developing innovative vaccines for diseases with unmet medical need. The company has a portfolio of two commercialised travel vaccines and two vaccines in clinical development for infectious diseases. We initiated coverage in April 2017.
Recent reports